Evidence map›Paper›PMID 34128115›Full record

ArticleJournal of neurology2022

The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.

Michal Lubomski, Xiangnan Xu, Andrew J Holmes, Jean Y H Yang, Carolyn M Sue, Ryan L Davis

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Gut-directed therapy in Parkinson's disease.Frontiers in pharmacology · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Gastrodin FromFrontiers in pharmacology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michal Lubomski *Department of Neurology, Clinical Admin 3E, Level 3, ASB, Royal North Shore Hospital, Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, 2065, Australia. mlub6241@uni.sydney.edu.au.ORCID http://orcid.org/0000-0003-4990-9293
Xiangnan Xu *School of Mathematics and Statistics, Sydney Precision Bioinformatics, University of Sydney, Camperdown, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-1910-6126
Andrew J HolmesSchool of Life and Environmental Sciences, University of Sydney, Camperdown, Sydney, NSW, Australia.
Jean Y H Yang *School of Mathematics and Statistics, Sydney Precision Bioinformatics, University of Sydney, Camperdown, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-5271-2603
Carolyn M Sue *Department of Neurology, Clinical Admin 3E, Level 3, ASB, Royal North Shore Hospital, Northern Sydney Local Health District, Reserve Rd, St Leonards, NSW, 2065, Australia.ORCID http://orcid.org/0000-0003-1255-3617
Ryan L Davis *Department of Neurogenetics, Faculty of Medicine and Health, Kolling Institute, University of Sydney and Northern Sydney Local Health District, St Leonards, NSW, Australia.ORCID http://orcid.org/0000-0003-0512-8989
The University of Sydney · AURoyal North Shore Hospital · AU

Funding

Parkinson's New South Wales Research Seed Grant
6 · The paper itself

Abstract

backgroundMicrobiome feedbacks are proposed to influence Parkinson's disease (PD) pathophysiology. A number of studies have evaluated the impact of oral medication on the gut microbiome (GM) in PD. However, the influence of PD device-assisted therapies (DATs) on the GM remains to be investigated.

objectivesTo profile acute gut microbial community alterations in response to PD DAT initiation.

methodsClinical data and stool samples were collected from 21 PD patients initiating either deep brain stimulation (DBS) or levodopa-carbidopa intestinal gel (LCIG) and ten spousal healthy control (HC) subjects. 16S amplicon sequencing of stool DNA enabled comparison of temporal GM stability between groups and with clinical measures, including disease alterations relative to therapy initiation.

resultsWe assessed GM response to therapy in the PD group by comparing pre-therapy (- 2 and 0 weeks) with post-therapy initiation timepoints (+ 2 and + 4 weeks) and HCs at baseline (0 weeks). Altered GM compositions were noted between the PD and HC groups at various taxonomic levels, including specific differences for DBS (overrepresentation of Clostridium_XlVa, Bilophila, Parabacteroides, Pseudoflavonifractor and underrepresentation of Dorea) and LCIG therapy (overrepresentation of Pseudoflavonifractor, Escherichia/Shigella, and underrepresentation of Gemmiger). Beta diversity changes were also found over the 4 week post-treatment initiation period.

conclusionsWe report on initial short-term GM changes in response to the initiation of PD DATs. Prior to the introduction of the DAT, a PD-associated GM was observed. Following initiation of DAT, several DAT-specific changes in GM composition were identified, suggesting DATs can influence the GM in PD.

Indexed as

Gastrointestinal MicrobiomeParkinson DiseaseAntiparkinson AgentsCarbidopaDrug CombinationsGelsHumansLevodopaAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopaDeep brain stimulation (DBS)Device-assisted therapiesGastrointestinal microbiomeGut microbiotaLevodopa–carbidopa intestinal gel (LCIG)Parkinson’s disease

Identifiers

PMID34128115
OpenAlexW3170522065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.